Inhaled Tranexamic Acid for Non-Massive Haemoptysis in a Rivaroxaban-Receiving Patient Not Responding to the Oral Form
  • Mugahid Eltahir
    Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
  • Mohamed Nabil Elshafei
    Clinical Pharmacy Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
  • Abdelnasser Elzouki
    Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar; Weill Cornell Medicine-Qatar, Doha, Qatar

Keywords

Tranexamic acid, haemoptysis, rivaroxaban, atrial fibrillation, COPD

Abstract

Haemoptysis is the expectoration of blood originating from the respiratory tract and occurs secondary to infection, malignancy, bronchiectasis or vascular disease. Its severity varies from minimal blood-streaked sputum to life-threatening haemorrhage. Therefore, prompt evaluation of the cause of the haemoptysis and its severity, and timely management are crucial. Although there is still no effective therapy for haemoptysis apart from treating the cause, inhaled tranexamic acid (TXA) might have a potential role in controlling non-massive haemoptysis. Here, we present a case of non-massive haemoptysis in a COPD patient with bronchiectasis on rivaroxaban for atrial fibrillation who responded to inhaled TXA following a failed trial of the oral formulation.

VIEW THE ENTIRE ARTICLE

References

  • Johnston H, Reisz G. Changing spectrum of hemoptysis: underlying causes in 148 patients undergoing diagnostic flexible fiberoptic bronchoscopy. Arch Intern Med 1989;149(7):1666–1668.
  • Unsal E, Koksal D, Cimen F, Taci Hoca N, Sipit T. Analysis of patients with hemoptysis in a reference hospital for chest diseases. Tuberk Toraks 2006;54(1):34–42.
  • Santiago S, Tobias J, Williams AJ. A reappraisal of the causes of hemoptysis. Arch Intern Med 1991;151(12):2449–2451.
  • Prasad R, Garg R, Singhal S, Srivastava P. Lessons from patients with hemoptysis attending a chest clinic in India. Ann Thorac Med 2009;4(1):10.
  • Ibrahim WH. Massive haemoptysis: the definition should be revised. Eur Respir J 2008;32(4):1131–1132.
  • Wand O, Guber E, Guber A, Shochet GE, Israeli-Shani L, Shitrit D. Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial. Chest 2018;154(6):1379–1384.
  • Dhanani JA, Roberts J, Reade MC. Nebulized tranexamic acid therapy for hemoptysis associated with submassive pulmonary embolism. J Aerosol Med Pulm Drug Deliv 2020;33(1):12–14.
  • Prutsky G, Domecq JP, Salazar CA, Accinelli R. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst Rev 2012;(4):CD008711.
  • Zhao Y, Li F, Liu Y, Shi Y, Li Z, Cao G, et al. Comparison of efficiency of inhaled and intravenous corticosteroid on pregnant women with COPD and the effects on the expression of PCT and hs-CRP. Exp Ther Med 2018;15(6):4717–4722.
  • Trend S, von Ungern, Sternberg BS, Devadason SG, Schultz A, Everard ML. Current options in aerosolised drug therapy for children receiving respiratory support. Anaesthesia 2017;72(11):1388–1397.
  • Views: 802
    HTML downloads: 91
    PDF downloads: 623


    Published: 2020-12-30
    Issue: 2020: Vol 7 No 12 (view)


    How to cite:
    1.
    Eltahir M, Elshafei MN, Abdelnasser Elzouki. Inhaled Tranexamic Acid for Non-Massive Haemoptysis in a Rivaroxaban-Receiving Patient Not Responding to the Oral Form. EJCRIM 2020;7 doi:10.12890/2020_001930.